Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc.
Your view on CPIX
Overview
What the company does, where it operates, and who runs it.
About Cumberland Pharmaceuticals Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- A. J. Kazimi MBA
- Headquarters
- 2525 West End Avenue, Nashville, TN, US
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- A. J. Kazimi MBA
- Headquarters
- 2525 West End Avenue, Nashville, TN, US
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally.
The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis.
In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension.
Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Cumberland Pharmaceuticals Inc., and the rating behind it. CPIX last traded at $6.39; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Cumberland Pharmaceuticals Inc.. Starting points for Cumberland Pharmaceuticals Inc.: EPS -$0.71, beta 0.10 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Cumberland Pharmaceuticals Inc.. Cumberland Pharmaceuticals Inc. paid $1.50 per share over the last year — a 23.5% yield at the current $6.39 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Cumberland Pharmaceuticals Inc.. Trailing twelve-month EPS for Cumberland Pharmaceuticals Inc. stands at -$0.71. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Cumberland Pharmaceuticals Inc.. Cumberland Pharmaceuticals Inc. has reported as a listed company since 2009. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Cumberland Pharmaceuticals Inc. valued side by side against its closest peers. Cumberland Pharmaceuticals Inc. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Cumberland Pharmaceuticals Inc., and how their positions are changing. At a $95.7M market value, institutional positions materially move Cumberland Pharmaceuticals Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Cumberland Pharmaceuticals Inc. executives and directors. Shares of Cumberland Pharmaceuticals Inc. have traded between $1.04 and $7.25 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Cumberland Pharmaceuticals Inc.. Cumberland Pharmaceuticals Inc. is a $95.7M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Cumberland Pharmaceuticals Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Cumberland Pharmaceuticals Inc.. Coverage tracks Cumberland Pharmaceuticals Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.